MDT

85.51

-0.66%↓

120.54

-0.91%↓

VEEV

168.35

+0.27%↑

HQY

86.03

+0.12%↑

NEOG

9.58

+0.84%↑

MDT

85.51

-0.66%↓

120.54

-0.91%↓

VEEV

168.35

+0.27%↑

HQY

86.03

+0.12%↑

NEOG

9.58

+0.84%↑

MDT

85.51

-0.66%↓

120.54

-0.91%↓

VEEV

168.35

+0.27%↑

HQY

86.03

+0.12%↑

NEOG

9.58

+0.84%↑

MDT

85.51

-0.66%↓

120.54

-0.91%↓

VEEV

168.35

+0.27%↑

HQY

86.03

+0.12%↑

NEOG

9.58

+0.84%↑

MDT

85.51

-0.66%↓

120.54

-0.91%↓

VEEV

168.35

+0.27%↑

HQY

86.03

+0.12%↑

NEOG

9.58

+0.84%↑

Home・Akciju saraksts・10X Genomics Inc (Class A)

10X Genomics Inc (Class A)

Atvērts

SektorsVeselības aprūpe

24.81 -4.72

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

24.61

Max

26.04

Galvenie mērījumi
By Trading Economics
Ienākumi	11M -16M
Pārdošana	17M 166M
Peļņas marža	-9.789
Darbinieki	1,178
EBITDA	-3.6M -20M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt
Prognoze 12 mēnešiem	-12.46% downside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 7. maijs

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	666M 3B
Iepriekšējā atvēršanas cena	29.53
Iepriekšējā slēgšanas cena	24.81

Ziņu noskaņojums

By Acuity

13%

87%

19 / 348 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Bullish Evidence

8.32 / 8.63 Atbalsts un pretestība

10X Genomics Inc (Class A) Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 19. apr. 23:48 UTC

Galvenie ziņu notikumi

Crude Oil, Refined Product Prices Moving Higher Amid Renewed Tensions in Strait of Hormuz -- OPIS

2026. g. 19. apr. 23:36 UTC

Galvenie ziņu notikumi

NAB Raises Provisions as Australian Banks Face Iran Risks -- Update

2026. g. 19. apr. 22:47 UTC

Galvenie ziņu notikumi

National Australia Bank Adds $215 Million in Iran-Driven Credit Provisions

2026. g. 19. apr. 21:14 UTC

Galvenie ziņu notikumi

Week Ahead for FX, Bonds: U.S. Retail Sales, PMI Data Due as Focus Remains on Middle East

2026. g. 19. apr. 21:14 UTC

Galvenie ziņu notikumi

Week Ahead for FX, Bonds: U.S. Retail Sales, PMI -2-

2026. g. 19. apr. 23:49 UTC

Tirgus saruna

Galvenie ziņu notikumi

Gold, Silver Decline Amid Renewed Inflation Concerns -- Market Talk

2026. g. 19. apr. 23:46 UTC

Tirgus saruna

Nikkei May Rise on Hopes for U.S.-Iran Peace Talks -- Market Talk

2026. g. 19. apr. 23:38 UTC

Galvenie ziņu notikumi

U.A.E. Asks U.S. About a Wartime Financial Lifeline -- Update

2026. g. 19. apr. 23:36 UTC

Tirgus saruna

Galvenie ziņu notikumi

Oil Climbs on Renewed Tensions Over Strait of Hormuz -- Market Talk

2026. g. 19. apr. 23:12 UTC

Galvenie ziņu notikumi

Spot Gold Falls 1.2%, Spot Silver Drops 1.6% on Renewed Middle East Tensions

2026. g. 19. apr. 23:10 UTC

Galvenie ziņu notikumi

Front-Month Brent Crude Oil Futures Rise 5.8% to $95.64 per Barrel

2026. g. 19. apr. 23:09 UTC

Galvenie ziņu notikumi

Front-Month WTI Crude Oil Futures Climb 7.2% to $89.86 per Barrel

2026. g. 19. apr. 23:08 UTC

Galvenie ziņu notikumi

Front-Month Crude Oil Futures Climb on Renewed Tensions Over Strait of Hormuz

2026. g. 19. apr. 21:20 UTC

Iegādes, apvienošanās, pārņemšana

Eli Lilly Nears Deal for Cancer Biotech -- WSJ

2026. g. 19. apr. 21:20 UTC

Iegādes, apvienošanās, pārņemšana

Announcement Could Come As Soon As Monday, Sources Say -- WSJ

2026. g. 19. apr. 21:20 UTC

Iegādes, apvienošanās, pārņemšana

Deal Expected to Be Worth Over $2B Plus Additional Milestones, Sources Say -- WSJ

2026. g. 19. apr. 21:20 UTC

Iegādes, apvienošanās, pārņemšana

Eli Lilly Nears Deal for Kelonia Therapeutics, Sources Say -- WSJ

2026. g. 19. apr. 20:03 UTC

Galvenie ziņu notikumi

U.A.E. Central Bank Governor Khaled Mohamed Balama Raised Swap Idea With Treasury Secretary Scott Bessent in Washington -- WSJ

2026. g. 19. apr. 20:03 UTC

Galvenie ziņu notikumi

Emiratis Portrayed Swap Proposal as Precautionary and Preliminary in Case Iran War Drags On -- WSJ

2026. g. 19. apr. 20:03 UTC

Galvenie ziņu notikumi

The U.A.E. Has Opened Talks with U.S. for Currency Swap -- WSJ

2026. g. 19. apr. 20:03 UTC

Galvenie ziņu notikumi

U.A.E. Asks U.S. for a Wartime Financial Lifeline -- WSJ

2026. g. 18. apr. 01:00 UTC

Galvenie ziņu notikumi

As Economic Pressures Mount, Will Iran or the U.S. Blink First? -- WSJ

2026. g. 17. apr. 22:58 UTC

Peļņas

Grupo Aeroportuario Del Pacifico: Announces Filing of 2025 Annual Report and Form 20-F

2026. g. 17. apr. 21:32 UTC

Tirgus saruna

Cerebras IPO Adds to Big Year For AI Firms Going Public -- Market Talk

2026. g. 17. apr. 21:22 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 17. apr. 21:22 UTC

Tirgus saruna

Moody's Downgrades Belgium to A1 -- Market Talk

2026. g. 17. apr. 20:52 UTC

Peļņas

Schwab Investors Get Spooked by JPMorgan's AI Strategy. The Big Worry Is Cash Sweeps. -- Barrons.com

2026. g. 17. apr. 20:50 UTC

Tirgus saruna

Peļņas

Iegādes, apvienošanās, pārņemšana

Tech, Media & Telecom Roundup: Market Talk

2026. g. 17. apr. 20:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 17. apr. 20:29 UTC

Peļņas

These Stocks Are Today's Movers: Royal Caribbean, Dow Inc., Netflix, Intel, Albemarle, Autoliv, Alcoa, and More -- Barrons.com

Salīdzinājums

Cenas izmaiņa

10X Genomics Inc (Class A) Prognoze

Cenas mērķis

By TipRanks

-12.46% uz leju

Prognoze 12 mēnešiem

Vidējais 22.83 USD -12.46%

Augstākais 32 USD

Zemākais 17 USD

Pamatojoties uz 13 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi 10X Genomics Inc (Class A) — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

13 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 13 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam 10X Genomics Inc (Class A) — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

8.32 / 8.63Atbalsts un pretestība

Recent bullish events outweigh bearish events.

There are no events.

Noskaņojums

By Acuity

19 / 348 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par 10X Genomics Inc (Class A)

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity and networks on a cell-by-cell basis; single cell gene expression flex; single cell immune profiling used to study the immune system; single cell Assay for Transposase Accessible Chromati (ATAC) solution to understand the epigenetic state; and single cell multiome ATAC + gene expression which enables simultaneous interrogation of both the RNA and chromatin accessibility, using ATAC in a single cell. The company also provides Visium platform which enables researchers to understand the spatial positions of biological analytes within tissues at high resolution; and Xenium platform for in situ analysis. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.